Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Physiomics ( (GB:PYC) ) is now available.
Physiomics has urged shareholders to vote against all resolutions tabled for a requisitioned general meeting on 29 April, which seek to remove the entire existing board and replace it with nominees of activist investor Mike Whitlow. The company argues that the proposed board changes are premature, risk disrupting its specialised life sciences strategy, could weaken independent oversight and minority shareholder protection, and lack the balance of experience required at a critical stage of its growth.
The current board further notes that proxy adviser ISS has recommended investors oppose all resolutions, reinforcing its view that continuity of leadership is essential to commercialise the value already created. With the vote to be held on a poll basis, Physiomics stresses the importance of individual shareholder participation given the size of the activist’s stake and encourages investors using platforms or nominees to act before internal voting deadlines.
Spark’s Take on PYC Stock
According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and persistent cash burn), partially offset by a low-leverage balance sheet and some improvement in price trend. Valuation is constrained by negative earnings and lack of dividend support.
To see Spark’s full report on PYC stock, click here.
More about Physiomics
Physiomics plc is a UK-based mathematical modelling, data science and biostatistics specialist focused on supporting the development of new therapeutics and personalised medicine solutions for biotech and pharma clients. Leveraging proprietary tools such as its Virtual Tumour technology, the company has contributed to more than 140 commercial projects spanning discovery, pre-clinical and clinical drug development.
Average Trading Volume: 7,809,171
Technical Sentiment Signal: Sell
Current Market Cap: £2.15M
For a thorough assessment of PYC stock, go to TipRanks’ Stock Analysis page.